Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Diacerein 1% Ointment in EB
NCT03472287Phase 1Completed
- Sponsor
- Castle Creek Biosciences
- Start
- May 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of AC-203 in epidermolysis bullosa (EB) (2 cohorts), sponsored by Castle Creek Biosciences. Primary endpoint: Plasma Concentrations of Diacerein and Rhein at Day 10. Started May 2018; status: completed.
02
Drugs
AC-203
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on NCT03472287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03472287.